Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference

AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will present at the H.C. Wainwright 24^th Annual Global Investment Conference being held September 12-14, 2022. A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on September 12, 2022 on Savara’s website at www.savarapharma.com/investors/events-presentations/ and archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005040/en/

Savara Inc. IR & PR

Anne Erickson

Senior Vice President, Chief of Staff

anne.erickson@savarapharma.com

(512) 851-1366

Source: Savara Inc.

FAQ

When is Savara Inc.'s CEO presenting at the H.C. Wainwright conference?

Matt Pauls, CEO of Savara Inc., will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.

What is the focus of Savara Inc. as a company?

Savara Inc. focuses on developing treatments for rare respiratory diseases, particularly autoimmune pulmonary alveolar proteinosis (aPAP).

How can I view Savara Inc.'s presentation at the conference?

The presentation can be viewed via a webcast on Savara's website starting at 7:00 AM ET on September 12, 2022.

What is molgramostim and its significance for Savara Inc.?

Molgramostim is Savara's lead program, an inhaled solution in Phase 3 development for treating autoimmune pulmonary alveolar proteinosis (aPAP).

How long will the webcast of Savara Inc.'s presentation be available?

The webcast of the presentation will be archived for 90 days after the event.